指南与共识消化、代谢与肾脏急症

低强度冲击波治疗在性医学中的应用——欧洲性医学学会(ESSM)临床推荐

Low-Intensity Shock Wave Therapy in Sexual Medicine-Clinical Recommendations from the European Society of Sexual Medicine (ESSM).
指南 / 共识 · J Sex Med · 2019-08-22
一句话结论低强度冲击波治疗安全性好、耐受性佳,但对勃起功能障碍疗效存疑;佩罗尼病患者疼痛可能获益但对病程进展无效;慢性前列腺炎/慢性盆腔疼痛综合征非首选,可考虑用于缓解疼痛。

欧洲性医学学会(ESSM)基于11项随机临床试验(RCT)和5项荟萃分析评估低强度冲击波治疗(LISWT)对勃起功能障碍(ED)、佩罗尼病(PD)和慢性前列腺炎/慢性盆腔疼痛综合征(CP/CPPS)的疗效并给出临床推荐。ED方面RCT结果存在争议且异质性高、样本量小,汇总分析显示勃起功能有总体正向效应但估计值小、队列异质性大。PD方面所有试验显示疼痛缓解但阴茎弯曲度和斑块大小无改善。CP/CPPS方面数据提示可能缓解疼痛但无证据支持疼痛缓解维持或随时间改善。结论认为LISWT安全耐受但ED疗效存疑,PD相关疼痛可能获益但对疾病进展无预期效果,CP/CPPS非首选但可考虑用于缓解疼痛。

要点

  • LISWT对ED的疗效存疑:11项RCT结果存在争议,汇总分析显示勃起功能有总体正向效应但估计值小、队列异质性大。
  • LISWT对PD可缓解疼痛,但对阴茎弯曲度和斑块大小无效果,不应预期影响疾病进展。
  • LISWT不是CP/CPPS的首选治疗,但可考虑作为缓解疼痛的选项之一;无证据支持疼痛缓解维持或随时间改善。
  • LISWT是安全且耐受性良好的操作,但作者认为其在性医学领域仍需进一步研究,几乎但尚未准备好用于临床实践。
  • 所有研究均由专家小组评估并据此提供临床实践推荐。

适用人群与场景

  • 勃起功能障碍(ED)患者:11项RCT和5项荟萃分析纳入,但各研究纳入标准差异大。
  • 佩罗尼病(PD)患者:4项RCT和1项荟萃分析纳入,各研究纳入标准差异很大。
  • 慢性前列腺炎/慢性盆腔疼痛综合征(CP/CPPS)患者:5项RCT纳入。

研究设计与关键结果

  • ED:11项RCT和5项荟萃分析;RCT结果对LISWT疗效存在争议,受高异质性和纳入患者数少影响;汇总数据分析显示勃起功能改善的总体正向效应,但估计值小且纳入患者队列异质性大。
  • PD:4项RCT和1项荟萃分析;所有试验显示疼痛缓解方面有阳性发现,但对阴茎弯曲度和斑块大小无效果;各研究纳入标准差异很大,需进一步研究。
  • CP/CPPS:5项RCT;数据显示对疼痛缓解可能有作用,但无证据支持疼痛缓解得以维持或疼痛随时间有任何改善。
  • 安全性:LISWT是安全且耐受性良好的操作。

证据类型、等级与局限

  • 证据类型:系统检索Medline和Embase数据库的RCT、荟萃分析及开放标签前瞻性或回顾性研究,由专家小组评估并提供临床实践推荐。
  • 证据分级:采用牛津2011标准提供证据水平,并使用牛津循证医学中心推荐意见进行分级。
  • 局限:RCT结果存在争议,受高异质性和纳入患者数少影响;汇总分析估计值小且队列异质性大;PD各研究纳入标准差异很大;CP/CPPS无证据支持疼痛缓解维持或随时间改善。

对床旁实践的改变

  • 作者认为LISWT在性医学领域需进一步研究,几乎但尚未准备好用于临床实践。
  • 作者认为LISWT对ED的疗效存疑,值得更多研究。
  • 作者认为报告PD相关疼痛的患者可能从LISWT获益,但对疾病进展不应预期有效果。
  • 作者认为LISWT不是CP/CPPS的主要治疗,但可考虑作为缓解疼痛的选项。

指南或共识出处

  • 欧洲性医学学会(ESSM)临床推荐,发表于J Sex Med 2019;16:1490-1505。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Low-intensity shockwave therapy (LISWT) has been investigated for the treatment of uroandrological disorders including erectile dysfunction (ED), Peyronie's disease (PD) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) with controversial findings.

AIM: To review the evidence on LISWT for ED, PD, and CP/CPPS and provide clinical recommendations on behalf of the European Society of Sexual Medicine.

METHODS: Medline and Embase databases were searched for randomized clinical trials (RCTs), meta-analyses and open-label prospective or retrospective studies investigating the effect of LISWT on ED, PD, or CP/CPPS.

OUTCOMES: The panel provided statements on clinically relevant questions concerning LISWT: (i) treatment efficacy, (ii) treatment protocol, (iii) clinical indications, and (iv) safety. The level of evidence was provided according to the Oxford 2011 criteria and graded using the Oxford Centre for Evidence-Based Medicine recommendations.

RESULTS: 11 RCTs and 5 meta-analyses investigated LISWT for ED. RCTs provided controversial results on the efficacy of LISWT and were affected by high heterogeneity and the small number of patients included. Pooled-data analysis showed an overall positive effect in terms of erectile function improvement but reported small estimates and included a largely heterogeneous cohort of patients. 4 RCTs and 1 meta-analysis assessed LISWT for PD. All trials showed positive findings in terms of pain relief but no effect on penile curvature and plaque size. Inclusion criteria vary widely among studies, and further investigation is needed. 5 RCTs investigated LISWT for CP/CPPS. Data showed a possible effect on pain relief, although there is no evidence supporting that pain relief was maintained or any improvement in pain over time.

CLINICAL IMPLICATIONS: LISWT needs to be further investigated in the context of sexual medicine and is almost but not yet ready for clinical practice.

STRENGTHS AND LIMITATIONS: All studies have been evaluated by a panel of experts providing recommendations for clinical practice.

CONCLUSIONS: LISWT is a safe and well-tolerated procedure but its efficacy for the treatment of ED is doubtful and deserves more investigation. Patients reporting pain associated with PD may benefit from LISWT, although no effect is expected on disease progression. LISWT is not a primary treatment for CP/CPPS, but it may be considered as an option to relieve pain. Capogrosso P, Frey A, Jensen CFS, et al. Low-Intensity Shock Wave Therapy in Sexual Medicine-Clinical Recommendations from the European Society of Sexual Medicine (ESSM). J Sex Med 2019;16:1490-1505.

来源:J Sex Med,查看原文。版权归原作者所有。

参考来源

  1. Capogrosso P, Frey A, Jensen CFS, et al. Low-Intensity Shock Wave Therapy in Sexual Medicine-Clinical Recommendations from the European Society of Sexual Medicine (ESSM). J Sex Med. 2019. PMID: 31447380. doi:10.1016/j.jsxm.2019.07.016

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。